MIRA•benzinga•
EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'This advancement expands the Company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 13, 2025 by benzinga